Research
Hormonal
Ketone bodies (specifically beta-hydroxybutyrate) act as signaling molecules that inhibit histone deacetylases (HDACs) and promote histone acetylation, thereby altering gene expression to support anti-oxidant and anti-inflammatory pathways.
This is a deep molecular mechanism. Practically, it means that the ketone bodies your body makes on a low-carb diet are actively turning on genes that protect your cells from aging and damage.
ModerateSupportsMEDIUM confidence
This is achieved by binding to class I and II histone deacetylases leading to enhanced acetylation nuclear histones in vitro and in several organs of mice, at βOHB concentration typical of nutritional ketosis.
Why this rating
Based on in vitro and animal studies; challenged by one study mentioned in the text.
Source
Ketone bodies: from enemy to friend and guardian angel
Hubert Kolb et al. · BMC Medicine · 2021
DOI 10.1186/s12916-021-02185-0
narrative_reviewCited 335×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Ketogenic diets result in significantly greater weight loss and improvements in metabolic markers (insulin, HbA1c) compared to standard low-fat or non-ketogenic calorie-restricted diets in overweight or obese individuals, particularly those with type 2 diabetes.Good
- Nutritional ketosis (via ketogenic diet or fasting) induces a hormetic adaptive response that improves cellular resilience, reduces oxidative/inflammatory stress, and protects organs like the heart and brain, primarily through the activation of Nrf2, sirtuins, and AMPK.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →